Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

CureVac, BioNTech, Valeo Pharma: Where is there still potential?

The race for vaccines against Covid-19 is fierce. Every day there are new water level reports - from setbacks to breakthroughs, everything is there. The Tübingen-based Company CureVac ( NASDAQ: CVAC ) recently started its phase study IIa in Peru and Panama. Around 700 people...
Nico Popp | October 16, 2020 |

Karyopharm Trades Up 60% on Positive Phase 3 Multiple Myeloma Results

Karyopharm Therapeutics shares set a new 52-week high price after the company reported that its Phase 3 BOSTON trial of XPOVIO® achieved significant increases in progression-free survival in patients suffering with multiple myeloma. Oncology-focused...
Streetwise Reports | March 3, 2020 |

Shares of Plant-Based Meat Company Spike 53% (and It's Not Beyond Meat)

This small-cap nutrascience stock hit a new 52-week high on May 6th, extending a run that has the stock up 147% over a five-day period. The buzz around Beyond Meat has been strong since the company's IPO last week, and subsequent 63% surge in stock price. Pe...
Streetwise Reports | May 7, 2019 |

XPhyto: The Cutting Edge of Medical Cannabis Science

At the forefront of the next wave of cannabis commercialization, is a German-focused company with headquarters in Vancouver, XPhyto Therapeutics Corp. (CSE: XPHY; FSE: 4XT) , that is building a much-coveted cannabis R&D cultivation facility in a converted nuclear bunker and o...
Marc Davis | November 12, 2019 |

Two Approvals Underscore Biotech's Pipeline Quality

The green lights and their implications are discussed in an H.C. Wainwright & Co. report. In a Jan. 22 research note, H.C. Wainwright & Co. analyst Ram Selvaraju reported that the European Commission approved the regimen consisting of Genmab A/S' (GMAB:NASD...
Streetwise Reports | January 30, 2020 |

Applied Therapeutics Investors Like the ACTION in Phase 2 Galactosemia Study

Applied Therapeutics' shares traded 25% higher today after the company reported positive topline results from its Pivotal Phase 2 ACTION Study of AT-007 for use in the treatment of galactosemia. The firm expects to file for regulatory approval of AT-007 in H2/20. This...
Streetwise Reports | January 9, 2020 |

Buzz on the Bullboards: Upbeat U.S. earnings good news for all?

Do rising tides truly lift all ships? We are in the midst of a strong earnings season and U.S. markets have reacted in kind. Strong earnings growth pushed Wall Street indices towards fresh record highs this past week. While activity moved lower earlier on, the belief ...
Jonathon Brown | February 8, 2024 |

Krill oil boom is real

There’s a new type of oil that’s causing a major stir in the markets. This oil boom has nothing to do with crude oil or energy though. But it still has the potential to be just as profitable. I’m talking about krill oil. ...
Andrew Mickey | October 28, 2012 |

Several Data Catalysts Expected in 2019 for 'Underappreciated Story'

An H.C. Wainwright & Co. report discussed what those are and why they could impact the biotech's valuation. In a March 18 research note, H.C. Wainwright & Co. analyst Andrew Fein purported that Constellation Pharmaceuticals Inc.'s (CNST:NASDAQ) "strong and balanced pi...
Streetwise Reports | March 25, 2019 |

Immuno-Oncology Firm to Collaborate on Third Clinical Trial with Genentech

Descriptions of the new study and upcoming data readouts for this California-based firm were provided in an H.C. Wainwright & Co. report. In an April 29 research note, H.C. Wainwright & Co. analyst Swayampakula Ramakanth reported that Forty Seven Inc. (FTSV...
Streetwise Reports | May 2, 2019 |
1 2 3